Thanks Jov88 - reply function not workingAs you point out so...

Thanks Jov88 - reply function not working

As you point out so well, oncarlytics is a huge step forward in precision medicine. In addition to efficacy, the aim is to minimise "on target, off tumour" effects.

Just some musing while we all wait for clinical results, a little piece of information from the Sydney roadshow has been ticking away in my mind and not going away. Prof Fong mentioned so briefly in his presentation that he was working on non-mammalian targets. Of course our current target is CD19, delivered by CF33.

I hadn't noticed this discussed on the IMU threads before, but apologise if I missed it.

I only had a moment with Prof Fong after the presentation and didn't have a chance to ask if he could expand for me, but my only thought was that a CF33 delivered non-mammalian target would by definition have a complete zero "on target, off tumour" effect. Even CF33-CD19 oncarlytics will have "on target, off tumour" effects on B cells, where CD19 is naturally expressed.

Obviously, anything like this would be many years away but I was truly stunned at the genius thinking. Imagine coming up with CF33-CD19 oncarlytics and then thinking up something that theoretically could be better!